| scholarly article | Q13442814 |
| P50 | author | Mark K. Slifka | Q97424936 |
| P2093 | author name string | Byung Park | |
| Lina Gao | |||
| Ariel M Slifka | |||
| P2860 | cites work | Tetanus-diphtheria-acellular pertussis vaccination for adults: an update | Q30238516 |
| More than 20 years after re-emerging in the 1990s, diphtheria remains a public health problem in Latvia | Q33553195 | ||
| Issues related to the decennial tetanus-diphtheria toxoid booster recommendations in adults | Q34218562 | ||
| Evaluation of adult dTPaP vaccination coverage in France: experience in Lyon city, 2010-2011 | Q34462808 | ||
| Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States | Q34655381 | ||
| Humoral responses to independent vaccinations are correlated in healthy boosted adults | Q35068548 | ||
| Impact of infection or vaccination on pre-existing serological memory | Q36339034 | ||
| Durability of Vaccine-Induced Immunity Against Tetanus and Diphtheria Toxins: A Cross-sectional Analysis | Q36783207 | ||
| Diphtheria in the United Kingdom, 1986-2008: the increasing role of Corynebacterium ulcerans | Q37778869 | ||
| Adult vaccination against tetanus and diphtheria: the European perspective | Q38856107 | ||
| Vaccination coverage among adults, excluding influenza vaccination - United States, 2013. | Q41474917 | ||
| Tetanus-toxoid emergency boosters: a reappraisal | Q42100703 | ||
| Potential protective immunogenicity of tetanus toxoid, diphtheria toxoid and Cross Reacting Material 197 (CRM197) when used as carrier proteins in glycoconjugates | Q43564881 | ||
| Antibodies to tetanus, diphtheria and pertussis among healthy adults vaccinated according to the French vaccination recommendations | Q44290230 | ||
| Duration of humoral immunity to common viral and vaccine antigens | Q45872621 | ||
| Adult vaccination coverage--United States, 2010. | Q46357793 | ||
| Plasma cell survival in the absence of B cell memory. | Q47113778 | ||
| Tetanus-diphtheria vaccination in adults: the long-term persistence of antibodies is not dependent on polyclonal B-cell activation and the defective response to diphtheria toxoid re-vaccination is associated to HLADRB1∗01 | Q57068845 | ||
| Tetanus surveillance--United States, 1995-1997 | Q64132915 | ||
| Meeting of the Strategic Advisory Group of Experts on immunization, April 2017 – conclusions and recommendations | Q64361168 | ||
| Evaluation of vaccination requirements to secure continuous antitoxin immunity to tetanus | Q69101175 | ||
| Tetanus--United States, 1982-1984 | Q69961546 | ||
| A population-based study on tetanus antitoxin levels in The Netherlands | Q73028945 | ||
| Diphtheria vaccine: WHO position paper – August 2017 | Q95375799 | ||
| Tetanus vaccines: WHO position paper – February 2017 | Q95472177 | ||
| P577 | publication date | 2020-02-25 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Incidence of Tetanus and Diphtheria in Relation to Adult Vaccination Schedules |
| Q101571352 | Enhanced post-licensure safety surveillance of a new recombinant acellular pertussis vaccine licensed as a monovalent (aP, Pertagen®) and tetanus, reduced-dose diphtheria combination (TdaP, Boostagen®) vaccine for immunization of adolescents and adu |
| Q94682546 | Two cases of imported respiratory diphtheria in Edinburgh, Scotland, October 2019 |
Search more.